Structure-Based Virtual Screening of the Nociceptin Receptor: Hybrid Docking and Shape-Based Approaches for Improved Hit Identification

The antagonist-bound crystal structure of the nociceptin receptor (NOP), from the opioid receptor family, was recently reported along with those of the other opioid receptors bound to opioid antagonists. We recently reported the first homology model of the ‘active-state’ of the NOP receptor, which when docked with ‘agonist’ ligands showed differences in the TM helices and residues, consistent with GPCR activation after agonist binding. In this study, we explored the use of the active-state NOP homology model for structure-based virtual screening to discover NOP ligands containing new chemical scaffolds. Several NOP agonist and antagonist ligands previously reported are based on a common piperidine scaffold. Given the structure–activity relationships for known NOP ligands, we developed a hybrid method that combines a structure-based and ligand-based approach, utilizing the active-state NOP receptor as well as the pharmacophoric features of known NOP ligands, to identify novel NOP binding scaffolds by virtual screening. Multiple conformations of the NOP active site including the flexible second extracellular loop (EL2) loop were generated by simulated annealing and ranked using enrichment factor (EF) analysis and a ligand–decoy dataset containing known NOP agonist ligands. The enrichment factors were further improved by combining shape-based screening of this ligand–decoy dataset and calculation of consensus scores. This combined structure-based and ligand-based EF analysis yielded higher enrichment factors than the individual methods, suggesting the effectiveness of the hybrid approach. Virtual screening of the CNS Permeable subset of the ZINC database was carried out using the above-mentioned hybrid approach in a tiered fashion utilizing a ligand pharmacophore-based filtering step, followed by structure-based virtual screening using the refined NOP active-state models from the enrichment analysis. Determination of the NOP receptor binding affinity of a selected set of top-scoring hits resulted in identification of several compounds with measurable binding affinity at the NOP receptor, one of which had a new chemotype for NOP receptor binding. The hybrid ligand-based and structure-based methodology demonstrates an effective approach for virtual screening that leverages existing SAR and receptor structure information for identifying novel hits for NOP receptor binding. The refined active-state NOP homology models obtained from the enrichment studies can be further used for structure-based optimization of these new chemotypes to obtain potent and selective NOP receptor ligands for therapeutic development.

[1]  Woody Sherman,et al.  Use of an Induced Fit Receptor Structure in Virtual Screening , 2006, Chemical biology & drug design.

[2]  Mark A. Weston,et al.  Synthesis and evaluation of N-3 substituted phenoxypropyl piperidine benzimidazol-2-one analogues as NOP receptor agonists with analgesic and sedative properties. , 2007, Bioorganic & medicinal chemistry.

[3]  F. Monsma,et al.  Moving from the Orphanin FQ Receptor to an Opioid Receptor Using Four Point Mutations* , 1996, The Journal of Biological Chemistry.

[4]  G. Adam,et al.  Synthesis of (1S,3aS)-8-(2,3,3a,4,5, 6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4. 5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties. , 2000, European journal of medicinal chemistry.

[5]  G. V. van Westen,et al.  GPCR structure and activation: an essential role for the first extracellular loop in activating the adenosine A2B receptor , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  Santiago Vilar,et al.  Application of Monte Carlo-based receptor ensemble docking to virtual screening for GPCR ligands. , 2013, Methods in enzymology.

[7]  J. Meunier,et al.  Different domains of the ORL1 and κ‐opioid receptors are involved in recognition of nociceptin and dynorphin A , 1998, FEBS letters.

[8]  N. Zaveri,et al.  Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): Ligand-based analysis of structural factors influencing intrinsic activity at NOP , 2005, The AAPS Journal.

[9]  Claudio N. Cavasotto,et al.  Representing receptor flexibility in ligand docking through relevant normal modes. , 2005, Journal of the American Chemical Society.

[10]  A. Rodomonte,et al.  Synthesis and pharmacological evaluation of 1,2-dihydrospiro[isoquinoline-4(3H),4'-piperidin]-3-ones as nociceptin receptor agonists. , 2008, Journal of medicinal chemistry.

[11]  Giuditta Bastanzio,et al.  Development of nociceptin receptor (NOP) agonists and antagonists , 2011, Medicinal research reviews.

[12]  N. Carruthers,et al.  High-Affinity, Non-Peptide Agonists for the ORL 1 (Orphanin FO/Nociceptin) Receptor , 2002 .

[13]  W. Greenlee,et al.  Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1. , 2007, Bioorganic & medicinal chemistry letters.

[14]  D. Tulshian,et al.  Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands: part 2. , 2009, Bioorganic & medicinal chemistry letters.

[15]  D. Tulshian,et al.  Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands. , 2007, Bioorganic & medicinal chemistry letters.

[16]  G Vassart,et al.  ORL1, a novel member of the opioid receptor family , 1994, FEBS letters.

[17]  Lei Shi,et al.  The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  F. Monsma,et al.  Creating a functional opioid alkaloid binding site in the orphanin FQ receptor through site-directed mutagenesis. , 1998, Molecular pharmacology.

[19]  Claudio N. Cavasotto,et al.  Ligand and Decoy Sets for Docking to G Protein-Coupled Receptors , 2012, J. Chem. Inf. Model..

[20]  Walter A. Korfmacher,et al.  The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety. , 2009, Bioorganic & medicinal chemistry letters.

[21]  Ajay N. Jain Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search , 2007, J. Comput. Aided Mol. Des..

[22]  James Andrew McCammon,et al.  Predictive Power of Molecular Dynamics Receptor Structures in Virtual Screening , 2011, J. Chem. Inf. Model..

[23]  Jonathan A. Javitch,et al.  Discovery of a Novel Selective Kappa-Opioid Receptor Agonist Using Crystal Structure-Based Virtual Screening , 2013, J. Chem. Inf. Model..

[24]  R. Nussinov,et al.  The role of dynamic conformational ensembles in biomolecular recognition. , 2009, Nature chemical biology.

[25]  I. Peretto,et al.  Lead generation and lead optimisation approaches in the discovery of selective, non-peptide ORL-1 receptor agonists and antagonists , 2001 .

[26]  William L. Jorgensen,et al.  Journal of Chemical Information and Modeling , 2005, J. Chem. Inf. Model..

[27]  Holger Gohlke,et al.  Target flexibility: an emerging consideration in drug discovery and design. , 2008, Journal of medicinal chemistry.

[28]  Yanli Wang,et al.  Structure-Based Virtual Screening for Drug Discovery: a Problem-Centric Review , 2012, The AAPS Journal.

[29]  G. Wishart,et al.  Structure-activity relationships and CoMFA of N-3 substituted phenoxypropyl piperidine benzimidazol-2-one analogues as NOP receptor agonists with analgesic properties. , 2008, Bioorganic & medicinal chemistry.

[30]  H. Pajouhesh,et al.  Medicinal chemical properties of successful central nervous system drugs , 2005, NeuroRX.

[31]  J. Deschamps,et al.  A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor. , 2004, Journal of medicinal chemistry.

[32]  G. Bignan,et al.  Recent advances towards the discovery of ORL-1 receptor agonists and antagonists , 2005 .

[33]  T. Vanderah,et al.  Recently patented and promising ORL-1 ligands: where have we been and where are we going? , 2010, Expert opinion on therapeutic patents.

[34]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[35]  J. Meunier,et al.  Distinct mechanisms for activation of the opioid receptor-like 1 and kappa-opioid receptors by nociceptin and dynorphin A. , 1999, Molecular pharmacology.

[36]  Woody Sherman,et al.  Generation of Receptor Structural Ensembles for Virtual Screening Using Binding Site Shape Analysis and Clustering , 2012, Chemical biology & drug design.

[37]  Ruben Abagyan,et al.  Consistent Improvement of Cross-Docking Results Using Binding Site Ensembles Generated with Elastic Network Normal Modes , 2009, J. Chem. Inf. Model..

[38]  M. Mortrud,et al.  Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a μ, δ or κ opioid receptor type , 1994 .

[39]  G. Adam,et al.  Synthesis of (1S,3aS)-8- (2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro [4.5]decan-4-one, a Potent and Selective Orphanin FQ (OFQ) Receptor Agonist with Anxiolytic-Like Properties. , 2000 .

[40]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[41]  C. Kozak,et al.  Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family , 1994, FEBS letters.

[42]  Bryan L. Roth,et al.  Structure of the Nociceptin/Orphanin FQ Receptor in Complex with a Peptide Mimetic , 2012, Nature.

[43]  F. Monsma,et al.  High-affinity, non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor. , 2000, Journal of medicinal chemistry.

[44]  J. Irwin,et al.  Benchmarking sets for molecular docking. , 2006, Journal of medicinal chemistry.

[45]  G. Bignan,et al.  3-(4-Piperidinyl)indoles and 3-(4-piperidinyl)pyrrolo-[2,3-b]pyridines as ligands for the ORL-1 receptor. , 2006, Bioorganic & medicinal chemistry letters.

[46]  N. Zaveri Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents. , 2003, Life sciences.

[47]  J. Lewis,et al.  Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors. , 2001, European journal of pharmacology.

[48]  W. Greenlee,et al.  Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2. , 2007, Bioorganic & medicinal chemistry letters.

[49]  G. Adam,et al.  ORL1 receptor ligands: structure-activity relationships of 8-cycloalkyl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-ones. , 2000, Bioorganic & medicinal chemistry letters.

[50]  M. Mortrud,et al.  Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type. , 1994, FEBS letters.

[51]  D. Koshland Application of a Theory of Enzyme Specificity to Protein Synthesis. , 1958, Proceedings of the National Academy of Sciences of the United States of America.

[52]  C. Topham,et al.  Functional inactivation of the nociceptin receptor by alanine substitution of glutamine 286 at the C terminus of transmembrane segment VI: evidence from a site-directed mutagenesis study of the ORL1 receptor transmembrane-binding domain. , 2000, Molecular pharmacology.

[53]  Pankaj R Daga,et al.  Homology modeling and molecular dynamics simulations of the active state of the nociceptin receptor reveal new insights intoagonist binding and activation , 2012, Proteins.